{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:25:14Z","timestamp":1793157914802,"version":"4.5.0"},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["314061271-TRR 205"],"award-info":[{"award-number":["314061271-TRR 205"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"INSERM","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>A somatic mutational hotspot in the SF3B1 gene was reported in lactotroph tumours. The aim of our study was to examine the prevalence of driver SF3B1 variants in a multicentre independent cohort of patients with lactotroph tumours and correlate with clinical data.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design and methods<\/jats:title>\n                  <jats:p>This was a retrospective, multicentre study involving 282 patients with lactotroph tumours (including 6 metastatic lactotroph tumours) from 8 European centres. We screened SF3B1 exon 14 hotspot for somatic variants using Sanger sequencing and correlated with clinicopathological data.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We detected SF3B1 variants in seven patients with lactotroph tumours: c.1874G &amp;gt; A (p.Arg625His) (n = 4, 3 of which metastatic) and a previously undescribed in pituitary tumours variant c.1873C &amp;gt; T (p.Arg625Cys) (n = 3 aggressive pituitary tumours). In two metastatic lactotroph tumours with tissue available, the variant was detected in both primary tumour and metastasis. The overall prevalence of likely pathogenic SF3B1 variants in lactotroph tumours was 2.5%, but when we considered only metastatic cases, it reached the 50%. SF3B1 variants correlated with significantly larger tumour size; higher Ki67 proliferation index; multiple treatments, including radiotherapy and chemotherapy; increased disease-specific death; and shorter postoperative survival.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>SF3B1 variants are uncommon in lactotroph tumours but may be frequent in metastatic lactotroph tumours. When present, they associate with aggressive tumour behaviour and worse clinical outcome.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ejendo\/lvad114","type":"journal-article","created":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T10:50:34Z","timestamp":1695034234000},"page":"372-378","source":"Crossref","is-referenced-by-count":38,"title":["Prevalence and clinical correlations of <i>SF3B1<\/i> variants in lactotroph tumours"],"prefix":"10.1093","volume":"189","author":[{"given":"Julia","family":"Simon","sequence":"first","affiliation":[{"name":"Medizinische Klinik und Poliklinik IV, LMU Klinikum, LMU M\u00fcnchen , Munich 80336 , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Gustavo","family":"Perez-Rivas","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik IV, LMU Klinikum, LMU M\u00fcnchen , Munich 80336 , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yining","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University of Erlangen-N\u00fcrnberg , Erlangen 91054 , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Chasseloup","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Assistance Publique-H\u00f4pitaux de Paris, H\u00f4pital Bic\u00eatre, Service d\u2019Endocrinologie et des Maladies de la Reproduction, Centre de R\u00e9f\u00e9rence des Maladies Rares de l\u2019Hypophyse , Le Kremlin-Bic\u00eatre 94275 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Lasolle","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Reference Center for Rare Pituitary Diseases HYPO, Claude Bernard Lyon 1 University, \u201cGroupement Hospitalier Est\u201d Hospices Civils de Lyon , Bron 69500 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Cortet","sequence":"additional","affiliation":[{"name":"Service d'Endocrinologie, CHRU de Lille , Lille 59037 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francoise","family":"Descotes","sequence":"additional","affiliation":[{"name":"Service de Biochimie Biologie Mol\u00e9culaire, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud , Pierre B\u00e9nite Cedex 69495 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Villa","sequence":"additional","affiliation":[{"name":"Neuropathology Department, Piti\u00e9-Salp\u00eatri\u00e8re University Hospital, AP-HP, Sorbonne Universit\u00e9 and Universit\u00e9 Paris Cit\u00e9, CNRS UMR8104, INSERM U1016, Institut Cochin , Paris 75014 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0735-8278","authenticated-orcid":false,"given":"Bertrand","family":"Baussart","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Assistance Publique-Hopitaux de Paris, Piti\u00e9-Salpetri\u00e8re University Hospital and Universit\u00e9 Paris Cit\u00e9, CNRS UMR8104, INSERM U1016, Institut Cochin , Paris 75014 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4844-8336","authenticated-orcid":false,"given":"Pia","family":"Burman","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Sk\u00e5ne University Hospital, Lund University , Malm\u00f6 214 28 , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Maiter","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, UCLouvain Cliniques Universitaires Saint-Luc , Bruxelles 1200 , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"von Selzam","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik IV, LMU Klinikum, LMU M\u00fcnchen , Munich 80336 , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Rotermund","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Division of Pituitary Surgery, University Medical Center Hamburg-Eppendorf , Hamburg 20251 , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Flitsch","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Division of Pituitary Surgery, University Medical Center Hamburg-Eppendorf , Hamburg 20251 , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5886-5486","authenticated-orcid":false,"given":"Jun","family":"Thorsteinsdottir","sequence":"additional","affiliation":[{"name":"Neurochirurgische Klinik und Poliklinik, LMU Klinikum, LMU M\u00fcnchen , Munich 81377 , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Jouanneau","sequence":"additional","affiliation":[{"name":"Pituitary and Skull Base Neurosurgical Department, Reference Center for Rare Pituitary Diseases HYPO, \u201cGroupement Hospitalier Est\u201d Hospices Civils de Lyon, \u201cClaude Bernard\u201d Lyon 1 University, H\u00f4pital Pierre Wertheimer , Lyon, Bron 69677 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Buchfelder","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University of Erlangen-N\u00fcrnberg , Erlangen 91054 , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5096-5722","authenticated-orcid":false,"given":"Philippe","family":"Chanson","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Assistance Publique-H\u00f4pitaux de Paris, H\u00f4pital Bic\u00eatre, Service d\u2019Endocrinologie et des Maladies de la Reproduction, Centre de R\u00e9f\u00e9rence des Maladies Rares de l\u2019Hypophyse , Le Kremlin-Bic\u00eatre 94275 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9517-338X","authenticated-orcid":false,"given":"Gerald","family":"Raverot","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Reference Center for Rare Pituitary Diseases HYPO, Claude Bernard Lyon 1 University, \u201cGroupement Hospitalier Est\u201d Hospices Civils de Lyon , Bron 69500 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7378-4374","authenticated-orcid":false,"given":"Marily","family":"Theodoropoulou","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik IV, LMU Klinikum, LMU M\u00fcnchen , Munich 80336 , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,9,13]]},"reference":[{"issue":"2","key":"2023091810490193200_lvad114-B1","doi-asserted-by":"crossref","first-page":"101290","DOI":"10.1016\/j.beem.2019.101290","article-title":"The epidemiology, diagnosis and treatment of prolactinomas: the old and the new","volume":"33","author":"Chanson","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"5","key":"2023091810490193200_lvad114-B2","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1530\/EJE-12-0236","article-title":"Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients","volume":"167","author":"Vroonen","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2023091810490193200_lvad114-B3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1530\/EJE-07-0248","article-title":"Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients","volume":"158","author":"Kreutzer","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2023091810490193200_lvad114-B4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000497331","article-title":"Surgery for prolactinomas to date","volume":"109","author":"Buchfelder","year":"2019","journal-title":"Neuroendocrinology"},{"issue":"1","key":"2023091810490193200_lvad114-B5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11102-019-00987-3","article-title":"Dopamine agonist resistant prolactinomas: any alternative medical treatment?","volume":"23","author":"Souteiro","year":"2020","journal-title":"Pituitary"},{"issue":"1","key":"2023091810490193200_lvad114-B6","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000495775","article-title":"Management of dopamine agonist-resistant prolactinoma","volume":"109","author":"Maiter","year":"2019","journal-title":"Neuroendocrinology"},{"issue":"4","key":"2023091810490193200_lvad114-B7","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/cen.14706","article-title":"Molecular genetic testing in the management of pituitary disease","volume":"97","author":"Coopmans","year":"2022","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"4","key":"2023091810490193200_lvad114-B8","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1530\/EJE-12-0763","article-title":"Genetic analysis in young patients with sporadic pituitary macroadenomas: besides AIP don\u2019t forget MEN1 genetic analysis","volume":"168","author":"Cuny","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2023091810490193200_lvad114-B9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11102-020-01085-5","article-title":"AIP variant causing familial prolactinoma","volume":"24","author":"Carty","year":"2021","journal-title":"Pituitary"},{"issue":"1","key":"2023091810490193200_lvad114-B10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/ng.3166","article-title":"Mutations in the deubiquitinase gene USP8 cause Cushing\u2019s disease","volume":"47","author":"Reincke","year":"2015","journal-title":"Nat Genet."},{"issue":"11","key":"2023091810490193200_lvad114-B11","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/cr.2016.114","article-title":"The genome-wide mutational landscape of pituitary adenomas","volume":"26","author":"Song","year":"2016","journal-title":"Cell Res."},{"issue":"7","key":"2023091810490193200_lvad114-B12","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1158\/1078-0432.CCR-16-0790","article-title":"Landscape of genomic alterations in pituitary adenomas","volume":"23","author":"Bi","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2023091810490193200_lvad114-B13","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ccell.2019.11.002","article-title":"Pangenomic classification of pituitary neuroendocrine tumors","volume":"37","author":"Neou","year":"2020","journal-title":"Cancer Cell"},{"issue":"5","key":"2023091810490193200_lvad114-B14","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.ajhg.2017.03.011","article-title":"Germline mutations in CDH23, encoding cadherin-related 23, are associated with both familial and sporadic pituitary adenomas","volume":"100","author":"Zhang","year":"2017","journal-title":"Am J Hum Genet."},{"issue":"4","key":"2023091810490193200_lvad114-B15","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s12022-019-09587-0","article-title":"The genomic landscape of sporadic prolactinomas","volume":"30","author":"De Sousa","year":"2019","journal-title":"Endocr Pathol."},{"issue":"12","key":"2023091810490193200_lvad114-B16","doi-asserted-by":"crossref","first-page":"e1022","DOI":"10.1002\/mgg3.1022","article-title":"Identification of a novel somatic mutation of POU6F2 by whole-genome sequencing in prolactinoma","volume":"7","author":"Miao","year":"2019","journal-title":"Mol Genet Genomic Med"},{"issue":"1","key":"2023091810490193200_lvad114-B17","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1038\/s41467-020-16052-8","article-title":"Somatic SF3B1 hotspot mutation in prolactinomas","volume":"11","author":"Li","year":"2020","journal-title":"Nat Commun."},{"key":"2023091810490193200_lvad114-B18","doi-asserted-by":"crossref","first-page":"616339","DOI":"10.3389\/fendo.2021.616339","article-title":"Case report: temozolomide treatment of refractory prolactinoma resistant to dopamine agonists","volume":"12","author":"Tang","year":"2021","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"3","key":"2023091810490193200_lvad114-B19","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3390\/jpm10030088","article-title":"Immunotherapy in corticotroph and lactotroph aggressive tumors and carcinomas: two case reports and a review of the literature","volume":"10","author":"Duhamel","year":"2020","journal-title":"J Pers Med"},{"issue":"1","key":"2023091810490193200_lvad114-B20","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s12885-015-1267-0","article-title":"Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas","volume":"15","author":"Gao","year":"2015","journal-title":"BMC Cancer"},{"issue":"12","key":"2023091810490193200_lvad114-B21","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/s41422-022-00736-5","article-title":"Integrated proteogenomic characterization across major histological types of pituitary neuroendocrine tumors","volume":"32","author":"Zhang","year":"2022","journal-title":"Cell Res."},{"issue":"4","key":"2023091810490193200_lvad114-B22","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1530\/EJE-22-0440","article-title":"Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients","volume":"187","author":"Burman","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"2023091810490193200_lvad114-B23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/978-3-7091-9183-5_12","article-title":"Pituitary adenomas with parasellar invasion","volume":"53","author":"Knosp","year":"1991","journal-title":"Acta Neurochir Suppl (Wien)"},{"issue":"1","key":"2023091810490193200_lvad114-B24","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00401-013-1084-y","article-title":"A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up","volume":"126","author":"Trouillas","year":"2013","journal-title":"Acta Neuropathol."},{"issue":"1","key":"2023091810490193200_lvad114-B25","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-17-0796","article-title":"European Society of Endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas","volume":"178","author":"Raverot","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2023091810490193200_lvad114-B26","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13046-022-02245-0","article-title":"The SF3B1(R625H) mutation promotes prolactinoma tumor progression through aberrant splicing of DLG1","volume":"41","author":"Guo","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"2023091810490193200_lvad114-B27","first-page":"50","article-title":"Molecular screening of pituitary adenomas for gene mutations and rearrangements","volume":"77","author":"Herman","year":"1993","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2023091810490193200_lvad114-B28","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/cr.2015.20","article-title":"Recurrent gain-of-function USP8 mutations in Cushing's disease","volume":"25","author":"Ma","year":"2015","journal-title":"Cell Res."},{"issue":"3","key":"2023091810490193200_lvad114-B29","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1210\/clinem\/dgaa853","article-title":"USP8 and TP53 drivers are associated with CNV in a corticotroph adenoma cohort enriched for aggressive tumors","volume":"106","author":"Uzilov","year":"2021","journal-title":"J Clin Endocrinol Metab."},{"issue":"7367","key":"2023091810490193200_lvad114-B30","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nature10496","article-title":"Frequent pathway mutations of splicing machinery in myelodysplasia","volume":"478","author":"Yoshida","year":"2011","journal-title":"Nature"},{"issue":"2","key":"2023091810490193200_lvad114-B31","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/ng.2523","article-title":"Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma","volume":"45","author":"Harbour","year":"2013","journal-title":"Nat Genet."},{"issue":"1","key":"2023091810490193200_lvad114-B32","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/ng.1032","article-title":"Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia","volume":"44","author":"Quesada","year":"2011","journal-title":"Nat Genet."},{"issue":"7","key":"2023091810490193200_lvad114-B33","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/bloodadvances.2019001127","article-title":"The K666N mutation in SF3B1 is associated with increased progression of MDS and distinct RNA splicing","volume":"4","author":"Dalton","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2023091810490193200_lvad114-B34","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40364-020-00220-5","article-title":"The biological function and clinical significance of SF3B1 mutations in cancer","volume":"8","author":"Zhou","year":"2020","journal-title":"Biomark Res"},{"issue":"1","key":"2023091810490193200_lvad114-B35","doi-asserted-by":"crossref","first-page":"10615","DOI":"10.1038\/ncomms10615","article-title":"Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage","volume":"7","author":"Alsafadi","year":"2016","journal-title":"Nat Commun."},{"issue":"5","key":"2023091810490193200_lvad114-B36","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.celrep.2015.09.053","article-title":"Cancer-associated SF3B1 hotspot mutations induce cryptic 3\u2032 splice site selection through use of a different branch point","volume":"13","author":"Darman","year":"2015","journal-title":"Cell Rep."},{"issue":"2","key":"2023091810490193200_lvad114-B37","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.molcel.2016.08.036","article-title":"Molecular architecture of SF3b and structural consequences of its cancer-related mutations","volume":"64","author":"Cretu","year":"2016","journal-title":"Mol Cell"},{"issue":"10","key":"2023091810490193200_lvad114-B38","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.3390\/cells8101118","article-title":"The E-cadherin and N-cadherin switch in epithelial-to-mesenchymal transition: signaling, therapeutic implications, and challenges","volume":"8","author":"Loh","year":"2019","journal-title":"Cells"},{"issue":"1","key":"2023091810490193200_lvad114-B39","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1186\/s12885-018-4845-0","article-title":"N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer","volume":"18","author":"Mrozik","year":"2018","journal-title":"BMC Cancer"},{"issue":"2","key":"2023091810490193200_lvad114-B40","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s10549-014-2927-5","article-title":"Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study","volume":"145","author":"Aleskandarany","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"2023091810490193200_lvad114-B41","doi-asserted-by":"crossref","first-page":"4386","DOI":"10.1091\/mbc.e05-03-0186","article-title":"Transendothelial migration of melanoma cells involves N-cadherin-mediated adhesion and activation of the beta-catenin signaling pathway","volume":"16","author":"Qi","year":"2005","journal-title":"Mol Biol Cell."},{"issue":"3","key":"2023091810490193200_lvad114-B42","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1365-2265.2007.03065.x","article-title":"The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma","volume":"68","author":"Fougner","year":"2008","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"5","key":"2023091810490193200_lvad114-B43","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1210\/jc.2009-2197","article-title":"The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response","volume":"95","author":"Fougner","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2023091810490193200_lvad114-B44","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000499382","article-title":"Clinical, pathological, and molecular factors of aggressiveness in lactotroph tumours","volume":"109","author":"Trouillas","year":"2019","journal-title":"Neuroendocrinology"},{"issue":"2","key":"2023091810490193200_lvad114-B45","doi-asserted-by":"crossref","first-page":"R69","DOI":"10.1530\/JME-12-0113","article-title":"Biomarkers of aggressive pituitary adenomas","volume":"49","author":"Mete","year":"2012","journal-title":"J Mol Endocrinol"},{"issue":"7","key":"2023091810490193200_lvad114-B46","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrendo.2014.64","article-title":"Aggressive pituitary adenomas\u2013diagnosis and emerging treatments","volume":"10","author":"Di Ieva","year":"2014","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"2023091810490193200_lvad114-B47","doi-asserted-by":"crossref","first-page":"e220338","DOI":"10.1530\/ERC-22-0338","article-title":"Outcome and prognostic factors for pituitary carcinomas: lessons from a systematic review","volume":"30","author":"Raymond","year":"2023","journal-title":"Endocr Relat Cancer."},{"issue":"4","key":"2023091810490193200_lvad114-B48","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/CMR.0000000000000071","article-title":"Rare SF3B1 R625 mutations in cutaneous melanoma","volume":"24","author":"Kong","year":"2014","journal-title":"Melanoma Res"},{"issue":"3","key":"2023091810490193200_lvad114-B49","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/CMR.0000000000000345","article-title":"Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma","volume":"27","author":"Hintzsche","year":"2017","journal-title":"Melanoma Res"},{"issue":"9","key":"2023091810490193200_lvad114-B50","doi-asserted-by":"crossref","first-page":"930","DOI":"10.18632\/oncotarget.26584","article-title":"Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas","volume":"10","author":"Quek","year":"2019","journal-title":"Oncotarget"},{"issue":"4","key":"2023091810490193200_lvad114-B51","doi-asserted-by":"crossref","first-page":"e1183","DOI":"10.1210\/clinem\/dgaa749","article-title":"Corticotroph aggressive pituitary tumors and carcinomas frequently harbor ATRX mutations","volume":"106","author":"Casar-Borota","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2023091810490193200_lvad114-B52","doi-asserted-by":"crossref","first-page":"791633","DOI":"10.3389\/fendo.2021.791633","article-title":"Resistance to dopamine agonists in pituitary tumors: molecular mechanisms","volume":"12","author":"Pivonello","year":"2022","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"14","key":"2023091810490193200_lvad114-B53","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/bloodadvances.2018027714","article-title":"The splicing factor Sf3b1 regulates erythroid maturation and proliferation via TGF\u03b2 signaling in zebrafish","volume":"3","author":"De La Garza","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"2023091810490193200_lvad114-B54","doi-asserted-by":"crossref","first-page":"e138315","DOI":"10.1172\/JCI138315","article-title":"Mutant SF3B1 promotes AKT- and NF-\u03baB-driven mammary tumorigenesis","volume":"131","author":"Liu","year":"2021","journal-title":"J Clin Invest."},{"issue":"2","key":"2023091810490193200_lvad114-B55","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccell.2018.07.003","article-title":"Synthetic lethal and convergent biological effects of cancer-associated spliceosomal gene mutations","volume":"34","author":"Lee","year":"2018","journal-title":"Cancer Cell"},{"key":"2023091810490193200_lvad114-B56","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.copbio.2019.01.003","article-title":"Therapeutic approaches to treat human spliceosomal diseases","volume":"60","author":"DeNicola","year":"2019","journal-title":"Curr Opin Biotechnol"},{"issue":"9","key":"2023091810490193200_lvad114-B57","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nchembio.2007.16","article-title":"Splicing factor SF3b as a target of the antitumor natural product pladienolide","volume":"3","author":"Kotake","year":"2007","journal-title":"Nat Chem Biol"},{"issue":"1","key":"2023091810490193200_lvad114-B58","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1186\/s13046-021-02153-9","article-title":"Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug","volume":"40","author":"Alors-Perez","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"2023091810490193200_lvad114-B59","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13046-022-02241-4","article-title":"SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1 splicing and mTOR\/\u00df-catenin pathways imbalances","volume":"41","author":"Fuentes-Fayos","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"2023091810490193200_lvad114-B60","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nm.4493","article-title":"H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers","volume":"24","author":"Seiler","year":"2018","journal-title":"Nat Med."},{"issue":"5","key":"2023091810490193200_lvad114-B61","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1158\/0008-5472.CAN-21-1843","article-title":"Cancer-associated SF3B1 mutations confer a BRCA-like cellular phenotype and synthetic lethality to PARP inhibitors","volume":"82","author":"Lappin","year":"2022","journal-title":"Cancer Res"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/189\/3\/372\/51663052\/lvad114.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/189\/3\/372\/51663052\/lvad114.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T10:50:59Z","timestamp":1695034259000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/189\/3\/372\/7276381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvad114","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9]]},"published":{"date-parts":[[2023,9,1]]}}}